相似文献
1
Where to go with new expensive treatments in NSCLC.
Br J Cancer. 1998 Jul;78(2):159-62. doi: 10.1038/bjc.1998.458.
2
[Established new drugs in the chemotherapy of non-small-cell lung carcinoma (NSCLC)].
Dtsch Med Wochenschr. 2000 Feb 25;125(8):225.
3
[Non-small-cell lung carcinoma (NSCLC): from ASCO 2004 to clinical practice].
Rev Pneumol Clin. 2004 Nov;60(5 Pt 3):4S46-4S52.
4
Non-small-cell lung cancer (NSCLC) chemotherapy for advanced disease: our experience in ten years.
Am J Clin Oncol. 1993 Apr;16(2):182-3.
5
Targeted biological treatments in NSCLC. Farnesyl transferase inhibitors.
Suppl Tumori. 2002 Jul-Aug;1(4):S49.
6
[Local and systemic therapy of non-small cell lung carcinoma (NSCLC)].
Onkologie. 2010;33 Suppl 5:1. doi: 10.1159/000313970. Epub 2010 May 14.
7
[The role of EGFR in non-small cell lung carcinoma].
Rev Med Suisse. 2009 May 20;5(204):1096-8, 1100-1.
8
[Do the new drugs improve therapeutic strategies for stage IV NSCLC?].
Rev Pneumol Clin. 2003 Nov;59(5 Pt 2):S21-2.
9
[Do the new drugs improve prognosis of stage IV NSCLC?].
Rev Pneumol Clin. 2003 Nov;59(5 Pt 2):S23-6.
10
Highlights in NSCLC from the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.
Clin Adv Hematol Oncol. 2012 Nov;10(11 Suppl 20):1-24.
引用本文的文献
1
Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study.
Br J Cancer. 2005 Oct 3;93(7):763-9. doi: 10.1038/sj.bjc.6602748.
2
A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma.
Br J Cancer. 2000 Oct;83(7):853-7. doi: 10.1054/bjoc.2000.1401.
本文引用的文献
1
Dose-finding study of irinotecan and cisplatin plus concurrent radiotherapy for unresectable stage III non-small-cell lung cancer [seecomments].
Br J Cancer. 1998 Jul;78(2):257-62. doi: 10.1038/bjc.1998.474.
2
A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. CPT-11 Lung Cancer Study Group.
Br J Cancer. 1998 Jul;78(2):251-6. doi: 10.1038/bjc.1998.473.
3
Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.
J Natl Cancer Inst. 1997 Nov 19;89(22):1673-82. doi: 10.1093/jnci/89.22.1673.
4
Defining the role of paclitaxel in lung cancer: summary of recent studies and implications for future directions.
Semin Oncol. 1997 Aug;24(4 Suppl 12):S12-153-S12-162.
5
Regulating the pharmaceutical industry.
BMJ. 1997 Jul 26;315(7102):200-1. doi: 10.1136/bmj.315.7102.200.
6
Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study.
J Clin Oncol. 1997 May;15(5):2097-102. doi: 10.1200/JCO.1997.15.5.2097.
7
8
Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group.
J Clin Oncol. 1993 May;11(5):873-8. doi: 10.1200/JCO.1993.11.5.873.
9
A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer.
J Natl Cancer Inst. 1994 May 4;86(9):673-80. doi: 10.1093/jnci/86.9.673.
10
A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.
N Engl J Med. 1994 Jan 20;330(3):153-8. doi: 10.1056/NEJM199401203300301.
Zotero 插件